The promise of ketamine for treatment-resistant depression: current evidence and future directions.
| Autor: | DeWilde KE; Mood and Anxiety Disorders Program, Icahn School of Medicine at Mount Sinai, New York, New York., Levitch CF; Mood and Anxiety Disorders Program, Icahn School of Medicine at Mount Sinai, New York, New York., Murrough JW; Mood and Anxiety Disorders Program, Icahn School of Medicine at Mount Sinai, New York, New York., Mathew SJ; Menninger Department of Psychiatry and Behavioral Sciences, Baylor College of Medicine, Houston, Texas., Iosifescu DV; Mood and Anxiety Disorders Program, Icahn School of Medicine at Mount Sinai, New York, New York. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Annals of the New York Academy of Sciences [Ann N Y Acad Sci] 2015 May; Vol. 1345, pp. 47-58. Date of Electronic Publication: 2015 Feb 03. |
| DOI: | 10.1111/nyas.12646 |
| Abstrakt: | Major depressive disorder (MDD) is one of the most disabling diseases worldwide and is becoming a significant public health threat. Current treatments for MDD primarily consist of monoamine-targeting agents and have limited efficacy. However, the glutamate neurotransmitter system has recently come into focus as a promising alternative for novel antidepressant treatments. We review the current data on the glutamate NMDA receptor antagonist ketamine, which has been shown in clinical trials to act as a rapid antidepressant in MDD. We also examine ketamine efficacy on dimensions of psychopathology, including anhedonia, cognition, and suicidality, consistent with the NIMH Research Domain Criteria initiative. Other aspects of ketamine reviewed in this paper include safety and efficacy, different administration methods, and the risks of misuse of ketamine outside of medical settings. Finally, we conclude with a discussion of glutamatergic agents other than ketamine currently being tested as novel antidepressants. (© 2015 New York Academy of Sciences.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|